ClinicalTrials.gov
ClinicalTrials.gov Menu

Protecting Young Special Risk Females From Cervical Cancer Through Human Papilloma Virus (HPV) Vaccination (HPV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00964210
Recruitment Status : Completed
First Posted : August 24, 2009
Last Update Posted : April 15, 2011
Sponsor:
Collaborators:
Brockhoff Foundation Australia
Shepherd Foundation Australia
Information provided by:
Murdoch Childrens Research Institute

Brief Summary:

A research project is currently being undertaken looking at Human Papilloma Virus (HPV) vaccination in special risk groups. It aims to see if young women with a chronic illness respond well to the HPV vaccine or whether they may require additional doses to ensure protective immunity. The four valent HPV vaccine protects against HPV types 16 & 18, cervical cancer and HPV types 6 & 11, anogenital warts.

The six special risk groups include:

Paediatric Rheumatological Disease Inflammatory Bowel Disease Acute Lymphoblastic Leukaemia Solid Organ Transplant Recipients (kidney and liver) Chronic Renal Disease Bone Marrow Transplants This immunity is measured by antibody levels of the HPV types, which requires a single blood test one month after the final dose of HPV vaccine.

This is compared to healthy controls using antibody response to HPV vaccine. This will assess directly whether these special risk groups respond as well to the HPV vaccine.


Condition or disease Intervention/treatment Phase
Cervical Cancer Drug: Licensed quadrivalent HPV vaccine, Gardasil Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 240 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Prospective Non Controlled Study of Immunogenicity of Human Papilloma Virus (HPV) Vaccine in Groups at Special Risk of Poor Vaccine Result
Study Start Date : March 2008
Actual Primary Completion Date : December 2010
Actual Study Completion Date : April 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cervical Cancer
U.S. FDA Resources


Intervention Details:
    Drug: Licensed quadrivalent HPV vaccine, Gardasil
    The dose of the four valent (4v) HPV vaccine is 0.5ml administered by intramuscular (IM)injection. The recommended schedule is 0, 2 and 6 months.


Primary Outcome Measures :
  1. Determine the HPV vaccine immunogenicity in females 12-26 years with six special risk groups at one month post the third and final HPV vaccination. Blood analysis taken at one month post third and final HPV vaccine to assess immunogenicity. [ Time Frame: One Month post HPV vaccination ]

Secondary Outcome Measures :
  1. Describe the safety of the HPV vaccine in the six study groups using self reports and liaison with treating sub specialist team. [ Time Frame: One month post third HPV vaccination ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Years to 26 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Females aged 12-26 years
  • Have been diagnosed by a specialist with one of the six chronic medical conditions described:

    1. Paediatric Rheumatological Disease
    2. Inflammatory Bowel Disease
    3. Acute Lymphoblastic Leukaemia
    4. Solid Organ Transplant Recipients (kidney and liver)
    5. Chronic Renal Disease
    6. Bone Marrow Transplant

Exclusion Criteria:

  • Previous immunisation with HPV vaccine Recognised contraindication to the receipt of the vaccine e.g. anaphylaxis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00964210


Locations
Australia, Victoria
Royal Childrens Hospital
Melbourne, Victoria, Australia, 3152
Sponsors and Collaborators
Murdoch Childrens Research Institute
Brockhoff Foundation Australia
Shepherd Foundation Australia
Investigators
Principal Investigator: Jim Buttery NHMRC CCRE in Childhood and Adolescent Immunisation

Responsible Party: Doctor Jim Buttery, Royal Childrens hospital
ClinicalTrials.gov Identifier: NCT00964210     History of Changes
Other Study ID Numbers: RCH CA27091
First Posted: August 24, 2009    Key Record Dates
Last Update Posted: April 15, 2011
Last Verified: August 2009

Keywords provided by Murdoch Childrens Research Institute:
Juvenile Idiopathic Arthritis
Inflammatory Bowel Disease
Acute Lymphoblastic Leukemia
Chronic Renal Disease
Solid Organ Transplant

Additional relevant MeSH terms:
Uterine Cervical Neoplasms
Papilloma
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female
Neoplasms, Squamous Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Vaccines
Immunologic Factors
Physiological Effects of Drugs